Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFINITY: Opicinumab in Relapsing MS
NCT03222973Phase 2Terminated
- Sponsor
- Biogen
- Start
- Nov 2017
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of opicinumab in multiple sclerosis (MS), sponsored by Biogen. Started Nov 2017; status: terminated.
02
Drugs
opicinumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03222973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222973.